269 related articles for article (PubMed ID: 32681436)
21. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
[TBL] [Abstract][Full Text] [Related]
22. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
[No Abstract] [Full Text] [Related]
23. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients.
Schmidt G; Guhl MM; Solomayer EF; Wagenpfeil G; Hammadeh ME; Juhasz-Boess I; Endrikat J; Kasoha M; Bohle RM
Arch Gynecol Obstet; 2022 Nov; 306(5):1689-1695. PubMed ID: 35377046
[TBL] [Abstract][Full Text] [Related]
25. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Huang X; Ding Q; Guo H; Gong Y; Zhao J; Zhao M; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Hum Pathol; 2021 Feb; 108():42-50. PubMed ID: 33221342
[TBL] [Abstract][Full Text] [Related]
26. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
[TBL] [Abstract][Full Text] [Related]
27. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection.
Cha YJ; Kim D; Bae SJ; Ahn SG; Jeong J; Lee HS; Jeon S; Yoo TK; Park WC; Yoon CI
Sci Rep; 2021 Oct; 11(1):19555. PubMed ID: 34599199
[TBL] [Abstract][Full Text] [Related]
29. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
30. Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer.
Imanishi S; Morishima H; Gotoh T
Jpn J Clin Oncol; 2022 Oct; 52(10):1167-1175. PubMed ID: 35766179
[TBL] [Abstract][Full Text] [Related]
31. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
[TBL] [Abstract][Full Text] [Related]
32. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.
Carter JM; Polley MC; Leon-Ferre RA; Sinnwell J; Thompson KJ; Wang X; Ma Y; Zahrieh D; Kachergus JM; Solanki M; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Thompson EA; Goetz MP
Clin Cancer Res; 2021 Oct; 27(20):5628-5637. PubMed ID: 34108182
[TBL] [Abstract][Full Text] [Related]
33. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
[TBL] [Abstract][Full Text] [Related]
34. Metaplastic breast cancer: Prognostic and therapeutic considerations.
Corso G; Frassoni S; Girardi A; De Camilli E; Montagna E; Intra M; Bottiglieri L; Margherita De Scalzi A; Fanianos DM; Magnoni F; Invento A; Toesca A; Conforti F; Bagnardi V; Viale G; Colleoni MA; Veronesi P
J Surg Oncol; 2021 Jan; 123(1):61-70. PubMed ID: 33047318
[TBL] [Abstract][Full Text] [Related]
35. Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.
Lee SE; Park HY; Lim SD; Han HS; Yoo YB; Kim WS
J Breast Cancer; 2020 Jun; 23(3):303-313. PubMed ID: 32595992
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
37. Multiplexed immunofluorescence identifies high stromal CD68
Wang J; Browne L; Slapetova I; Shang F; Lee K; Lynch J; Beretov J; Whan R; Graham PH; Millar EKA
Sci Rep; 2021 Nov; 11(1):21608. PubMed ID: 34732817
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients With Triple-negative Breast Cancer.
Chu J; Yeo MK; Lee SH; Lee MY; Chae SW; Kim HS; DO SI
In Vivo; 2022; 36(6):2890-2898. PubMed ID: 36309362
[TBL] [Abstract][Full Text] [Related]
39. Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
Morgan E; Suresh A; Ganju A; Stover DG; Wesolowski R; Sardesai S; Noonan A; Reinbolt R; VanDeusen J; Williams N; Cherian MA; Li Z; Young G; Palettas M; Stephens J; Liu J; Luff A; Ramaswamy B; Lustberg M
World J Surg Oncol; 2020 Jan; 18(1):11. PubMed ID: 31937323
[TBL] [Abstract][Full Text] [Related]
40. Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes.
Ntostoglou K; Theodorou SDP; Proctor T; Nikas IP; Awounvo S; Sepsa A; Georgoulias V; Ryu HS; Pateras IS; Kittas C
Cancer Immunol Immunother; 2024 Feb; 73(3):46. PubMed ID: 38349444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
